A Digital Approach to Treat Type 2 Diabetes Gains Momentum

Better Therapeutics has completed enrollment for its pivotal study to evaluate its prescription digital therapeutic.

MDDI Staff

November 22, 2021

1 Min Read
designer491 / Alamy Stock

Better Therapeutics has completed enrollment of its pivotal study to evaluate the safety and efficacy of BT-001 for the treatment of type 2 diabetes. The San Francisco, CA-based company’s BT-001 is a prescription digital therapeutic that delivers a novel form of cognitive behavioral therapy to patients with uncontrolled type 2 diabetes. 

The firm said it enrolled 662 patients – exceeding its target.

If positive, study results may support a regulatory submission for marketing authorization from FDA. Exploratory endpoint data captured during this study, including change in insulin resistance, blood lipids, inflammation, blood pressure and weight, could accelerate the development of Better Therapeutics’ product candidates to treat other cardiometabolic conditions.

This year has been tremendous for Better Therapeutics. The company went public through a Special Purpose Acquisition Merger (SPAC) with Mountain Crest Acquisition Corp. II. Better Therapeutics raised a total of $110 million in proceeds in the merger.

David Perry, chairman and co-founder of Better Therapeutics spoke was featured on the 21st episode of the Let’s Talk Medtech podcast and discussed the company’s efforts and going through the SPAC process.  You can find the episode below.



Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like